These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 23494240)

  • 1. Comprehensive assessment of the association of ERCC2 Lys751Gln polymorphism with susceptibility to cutaneous melanoma.
    Dong Y; Zhuang L; Ma W
    Tumour Biol; 2013 Apr; 34(2):1155-60. PubMed ID: 23494240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative assessment of the association between XPC Lys939Gln polymorphism and cutaneous melanoma risk.
    Zhou L; Lu Y; Yang G; Wu J
    Tumour Biol; 2014 Feb; 35(2):1427-32. PubMed ID: 24277375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive assessment of associations between ERCC2 Lys751Gln/Asp312Asn polymorphisms and risk of non- Hodgkin lymphoma.
    Zhou JY; He LW; Liu J; Yu HL; Wei M; Ma WL; Shi R
    Asian Pac J Cancer Prev; 2014; 15(21):9347-53. PubMed ID: 25422223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. XPD Lys751Gln and Asp312Asn polymorphisms and susceptibility to skin cancer: a meta-analysis of 17 case-control studies.
    Zhu HL; Bao JM; Lin PX; Li WX; Zou ZN; Huang YE; Chen Q; Shen H
    Asian Pac J Cancer Prev; 2014; 15(16):6619-25. PubMed ID: 25169498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Xeroderma pigmentosum group D polymorphisms and esophageal cancer susceptibility: a meta-analysis based on case-control studies.
    Yang R; Zhang C; Malik A; Shen ZD; Hu J; Wu YH
    World J Gastroenterol; 2014 Nov; 20(44):16765-73. PubMed ID: 25469049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of excision repair cross-complementing group 2 gene Lys751Gln and Asp312Asn polymorphisms in melanoma risk.
    Zhou X; Zeng Y; Jiang H; Xia L; Liu C
    Melanoma Res; 2018 Aug; 28(4):311-318. PubMed ID: 29768284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between the XPD/ERCC2 Lys751Gln polymorphism and risk of cancer: evidence from 224 case-control studies.
    Wu KG; He XF; Li YH; Xie WB; Huang X
    Tumour Biol; 2014 Nov; 35(11):11243-59. PubMed ID: 25113251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. XPD Lys751Gln polymorphism and esophageal cancer susceptibility: a meta-analysis of case-control studies.
    Ding DP; Ma WL; He XF; Zhang Y
    Mol Biol Rep; 2012 Mar; 39(3):2533-40. PubMed ID: 21667112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ERCC2 Lys751Gln polymorphism is associated with lung cancer among Caucasians.
    Zhang J; Gu SY; Zhang P; Jia Z; Chang JH
    Eur J Cancer; 2010 Sep; 46(13):2479-84. PubMed ID: 20627704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pooled analysis of the ERCC2 Asp312Asn polymorphism and esophageal cancer susceptibility.
    Wen F; Zhao Z; Liu C; Yin Q; Weng J; Wang Y; Ma Y
    Tumour Biol; 2014 Apr; 35(4):2959-65. PubMed ID: 24234258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of ERCC1 C8092A and ERCC2 Lys751Gln polymorphisms with the risk of glioma: a meta-analysis.
    Xin Y; Hao S; Lu J; Wang Q; Zhang L
    PLoS One; 2014; 9(4):e95966. PubMed ID: 24763305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. XPD Lys751Gln polymorphism and esophageal cancer risk: a meta-analysis involving 2288 cases and 4096 controls.
    Yuan L; Cui D; Zhao EJ; Jia CZ; Wang LD; Lu WQ
    World J Gastroenterol; 2011 May; 17(18):2343-8. PubMed ID: 21633601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of XPD polymorphisms on digestive tract cancers risk: a meta-analysis.
    Du H; Guo N; Shi B; Zhang Q; Chen Z; Lu K; Shu Y; Chen T; Zhu L
    PLoS One; 2014; 9(5):e96301. PubMed ID: 24787743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complex association between ERCC2 gene polymorphisms, gender, smoking and the susceptibility to bladder cancer: a meta-analysis.
    Wu Y; Yang Y
    Tumour Biol; 2014 Jun; 35(6):5245-57. PubMed ID: 24504678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between XPD Lys751Gln polymorphism and risk of head and neck cancer: a meta-analysis.
    Yuan H; Niu YM; Wang RX; Li HZ; Chen N
    Genet Mol Res; 2011 Nov; 10(4):3356-64. PubMed ID: 22179996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. XPD Lys751Gln and Asp312Asn polymorphisms and gastric cancer susceptibility: a meta-analysis of case-control studies.
    Yin QH; Liu C; Hu JB; Meng RR; Li L; Wang YJ
    Asian Pac J Cancer Prev; 2013; 14(1):231-6. PubMed ID: 23534729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphisms of excision repair gene XPD Lys751Gln and hOGG1 Ser326Cys might not be associated with hepatocellular carcinoma risk: a meta-analysis.
    Zhang RC; Mou SH
    Tumour Biol; 2013 Apr; 34(2):901-7. PubMed ID: 23271362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. XRCC1 and XPD genetic polymorphisms and susceptibility to age-related cataract: a meta-analysis.
    Chi XX; Liu YY; Shi SN; Cong Z; Liang YQ; Zhang HJ
    Mol Vis; 2015; 21():335-46. PubMed ID: 25873778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. XPD Lys751Gln polymorphisms and the risk of esophageal cancer: an updated meta-analysis.
    Guo XF; Wang J; Lei XF; Zeng YP; Dong WG
    Intern Med; 2015; 54(3):251-9. PubMed ID: 25748732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of association between XPD Lys751Gln and Asp312Asn polymorphisms and colorectal cancer risk: a meta-analysis of case-control studies.
    Zhang Y; Ding D; Wang X; Zhu Z; Huang M; He X
    Int J Colorectal Dis; 2011 Oct; 26(10):1257-64. PubMed ID: 21541661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.